P Palthera

Common questions

Cartalax — questions, answered plainly.

6 research-context questions about Cartalax. Answers stay neutral and reference what is published in the peer-reviewed literature — no dosing, no human-use guidance, no extrapolation beyond what the cited studies report.

View full Cartalax profile Subscribe to updates
  1. 01

    What is Cartalax?

    Cartalax is a synthetic tripeptide (Ala-Glu-Asp / AED) developed by the Khavinson research group at the St Petersburg Institute of Bioregulation and Gerontology. It is part of the 'short peptide' family the Khavinson group has published on for over two decades.

  2. 02

    Is Cartalax FDA-approved?

    No. Cartalax is not FDA-approved, MHRA-approved, or EMA-approved. Published evidence is preclinical only.

  3. 03

    What does the cited Cartalax research show?

    Ashapkin 2020 (Molecular Biology Reports, PMID 32399807) reports AED (Cartalax), KED, and KE tripeptides modulated IGF1, FOXO1, TERT, TNKS2, and NFκB gene expression in human mesenchymal stem-cell aging cultures. Chalisova 2015 (Bull Exp Biol Med, PMID 26033601) reports AED (T-31) modulated cell-renewal markers in organotypic kidney cultures from young and old rats.

  4. 04

    Is Cartalax the same as Pinealon?

    No. Both are Khavinson short peptides, but Cartalax is Ala-Glu-Asp (AED) and Pinealon is Glu-Asp-Arg (EDR). They are distinct tripeptides with different sequences and primary cited models.

  5. 05

    Why is the evidence base concentrated in one research group?

    The Khavinson research network in St Petersburg has produced the majority of peer-reviewed Cartalax / AED literature. Independent replication outside this network is limited; this is a documented evidence caveat rather than an editorial judgement.

  6. 06

    What are the evidence caveats for Cartalax?

    No controlled human trials are indexed on PubMed. All cited primary evidence originates from the Khavinson research network. Findings are model-specific (organotypic and cell-culture) and are not extrapolated to therapeutic use.

Important

These answers are not medical advice.

Cartalax is referenced in research literature only. Palthera does not provide dosage, cycling, stacking, or injection guidance, and content is not intended to support consumer or therapeutic use. Speak to a qualified clinician for any health decisions.